|
||||||||||||||
 |
||||||||||||||
|
|
JACI Highlights - September 2009Determination of the clinical onset of action of sublingual immunotherapyAs reported in the September 2009 issue of The Journal of Allergy and Clinical Immunology , Horak et al. used an allergen challenge chamber (ACC) to investigate the onset of action of a 5-grass-pollen 300IR tablet in sublingual immunotherapy (SLIT) for seasonal allergic rhinoconjunctivitis (SAR). SLIT's onset of action determination is important for optimal preseasonal treatment duration assurance. A total of 89 adult patients with SAR to grass pollen were treated daily for 4 months with either active or placebo. Standardized challenges in the ACC (with a constant pollen concentration) were performed before treatment and after 1 week and 1, 2 and 4 months of treatment. The patients scored their rhinoconjunctivitis symptoms every 15 minutes during these challenges. Comparing the symptom score between the groups (active vs placebo), the authors observed a diminished score (although not statistically significant) after the first week of 300IR 5-grass pollen SLIT treatment and a significant reduction after 1 month (P = .0042), 2 months (P = .0203), and 4 months (P = .0007) of treatment. The authors concluded that the 5-grass-pollen SLIT tablets had a significant effect (versus placebo) on SAR from the first month of treatment onward. This is the first time that the onset of action of a SLIT tablet has been assessed. “Early onset of action of a five grass pollen 300IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber” by Horak el al. (JACI September 2009 Volume 124 No. 3) |
||||||||||||
|
© 1996-2009 · All Rights Reserved · American Academy of Allergy Asthma & Immunology |
||||||||||||||
